

Online Supplement
Health Status Progression Measured Using Weekly Telemonitoring of COPD
Assessment Test Scores Over 1 Year and Its Association with COPD Exacerbations

Paul Jones, MD, PhD^{1a} Toru Soutome, BPharm^{2a,b} Taizo Matsuki, PhD^{2a} Masahiro Shinoda, MD, PhD³ Osamu Hataji, MD, PhD⁴ Motohiko Miura, MD, PhD⁵ Masaharu Kinoshita, MD⁶ Akira Mizoo, MD⁷ Kazunori Tobino, MD⁸ Takanobu Nishi, MSc² Takeo Ishii, MD, PhD^{2b} Yoko Shibata, MD, PhD⁹

^aContributed equally

^bAt the time of the study

¹GSK, Brentford, Middlesex, United Kingdom

²Japan Medical & Development, GSK K.K, Tokyo, Japan

³Department of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan

⁴Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan

⁵Department of Respiratory Medicine, Tohoku Rosai Hospital, Miyagi, Japan

⁶Department of Respiratory Medicine, Nagata Hospital, Fukuoka, Japan

⁷Department of Pulmonary Medicine, Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Tokyo, Japan

⁸Department of Respiratory Medicine, Iizuka Hospital, Fukuoka, Japan

⁹Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan

Supplementary Table 1. Full study inclusion and exclusion criteria

Inclusion criteria
Capable of giving signed informed consent, including compliance with the requirements and restrictions required for the study
≥40 years of age inclusive at the time of inclusion in the study
An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society and Japanese Respiratory Society COPD and ACO guidelines.
Treated with inhaled LAMA and/or LABA as maintenance medication at the screening visit. LAMA/ LABA or ICS combinations will be allowed but inhaled triple therapy (e.g., ICS/LAMA/LABA) will not be allowed at baseline visit. Other short-acting bronchodilators, roflumilast, systemic steroids, or antibiotics medications are permitted.
Lung function test in the 12 months prior to study.
Exclusion criteria
Unable or unwilling to use the required telemonitoring device/ system.
Treated with ICS/LAMA/LABA triple combination at screening visit or during past 3 months before screening visit even open or closed combinations.
Treated with biologicals during past 6 months before screening visit such as omalizumab or mepolizumab.
Pregnant or lactating or are planning on becoming pregnant during the study.
Concurrently participating in another clinical trial, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/ product (pharmaceutical product).

ACO, Asthma-COPD Overlap; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β_2 -agonist; LAMA, long-acting muscarinic antagonist.

Supplementary Figure 1. Individual CAT Score Plot



